Clinical Trial Finder

Inclusion Criteria:

• - Age ≥ 1 year (including cut-off value), gender is not limited.

• - Expected survival time ≥ 3 months.

• - Karnofsky score (> 16 years) or Lansky score (≤ 16 years) > 60 points.

• - Meet the clinical diagnostic criteria and be diagnosed as recurrent / refractory neuroblastoma.

For first-line standard treatment, please refer to the consensus of experts in the diagnosis and treatment of Pediatric Neuroblastoma (Chinese Journal of Pediatric surgery, Volume 36, No. 1, 2015), the guidelines for the diagnosis and treatment of Pediatric Neuroblastoma of 2019 by the Health Commission, and the consensus of experts in the diagnosis and treatment of Pediatric Neuroblastoma (CCCG-NB-2021 Program) (Chinese Journal of Pediatric surgery, Volume 43, No. 7, 2022) 1. Recurrence is defined as the determination of recurrence after remission after at least first-line standard treatment. 2. Refractory is defined as a person who is not in remission after at least 4 cycles of chemotherapy (≥ 2 chemotherapeutic drugs, including alkylating agents and platinum)

• - The tumor tissue samples of the subjects were stained by immunohistochemistry (IHC) to show that the expression intensity of B7-H3 on the surface of tumor cell membranes was 1+ or above, and the proportion of positive staining of tumor cell membranes was ≥1% - At least one measurable lesion defined by RECISTv1.1 criteria, and at least one lesion that can be irradiated (except bone marrow) - Subjects with lesions only in the bone marrow may also be enrolled (without irradiation) - Liver and kidney function, cardiopulmonary function must meet the following requirements: 1.

Total bilirubin ≤ 3 × ULN;ALT and AST ≤ 5 × ULN. 2. Creatinine≤2 ULN. 3. Left ventricular ejection fraction ≥ 50% 4. Blood oxygen saturation ≥ 92%

• - Patients and/or their guardians understand the trial and have signed informed consent.

Exclusion Criteria:

• - Patients who were judged by the investigator to require long-term immunosuppressive therapy at the time of screening.

• - Cerebrovascular accident or seizure occurred within 6 months before signing the informed consent.

• - Malignant tumors other than neuroblastoma, excluding carcinoma in situ.

• - Hepatitis B surface antigen (HBsAg) positive; hepatitis B core antibody (HBcAb) positive and peripheral blood hepatitis B virus (HBV) DNA titer detection not within the normal reference range; hepatitis C virus (HCV) antibody positive and peripheral blood type C Hepatitis virus (HCV) RNA positive; human immunodeficiency virus (HIV) antibody positive; cytomegalovirus (CMV) DNA positive; syphilis positive.

• - Serious cardiac disease: including but not limited to unstable angina, myocardial infarction (within 6 months prior to screening), congestive heart failure (New York Heart Association [NYHA] classification ≥ grade III), severe arrhythmia.

• - Unstable systemic disease as judged by the investigator: including but not limited to severe liver, kidney or metabolic disease requiring drug therapy.

• - Presence of chronic progressive neurological disease.

• - Patients who have not recovered from acute toxic effects of prior treatment.

• - Active or uncontrolled infection requiring systemic treatment (except mild urogenital and upper respiratory tract infections) - Pregnancy-capable female subjects who plan to become pregnant within 2 years of cell reinfusion; or male subjects whose partners plan to become pregnant within 2 years of cell reinfusion.

• - Those who have received CAR-T therapy or other gene-modified cell therapy before screening.

• - Participated in other clinical studies within 1 month before screening.

• - Subjects screened for evidence of central nervous system involvement.

• - For patients with liver metastases, the distribution of liver metastases exceeds 1/2 of the liver.

• - According to the judgment of the investigators, it does not meet the situation of cell preparation.

- Other circumstances deemed inappropriate by investigators

In the dose-escalation phase of the Phase I clinical trial, a traditional 3+3 trial design was adopted, with a total of 3 dose groups designed. The dose of T/kg was gradually increased, and a total of 12-18 subjects with relapsed/refractory neuroblastoma were enrolled.Within each dose group, the next subject can be dosed after the previous subject has completed at least 14 days of safety observations. After the last subject of each dose group completed the dose-limited toxicity (DLT) evaluation within 28 days after a single dose, the SMC (Safety Monitoring Committee) agreed to enter the next dose group after evaluating the clinical safety data. After that, the enrolment treatment for the next dose group can be started.When 1 DLT occurs in 3 subjects in a dose group, 3 additional subjects in the same dose group (up to 6 subjects in this dose group complete the DLT assessment): If the additional 3 subjects If no DLT occurs, continue dose escalation; if 1 out of 3 additional subjects develops DLT, stop dose escalation; if > 1 of 3 additional subjects develops DLT DLT, then stop the dose escalation, and at the same time need to reduce a dose to continue to enroll 3 subjects for DLT evaluation. In the dose expansion phase of the Phase I clinical trial, SMC will review the obtained safety and available data on efficacy, PK, immunogenicity, etc., and give the RP2D dose after comprehensive evaluation. In the dose expansion phase, the RP2D dose group will continue to be enrolled 3 ~6 subjects, further clarify the preliminary efficacy and safety of RP2D.

Arms

Experimental: T cell injection targeting TAA06 chimeric antigen receptor

The subjects, who sign the informed consent forms and been screened by inclusion/exclusion criteria, will be assigned into 2.0 × 10^6, 4.0 × 10^6 and 8.0 × 10^6 CAR-T/kg groups in order of sequence.

Interventions

Biological: - T cell injection targeting B7-H3 chimeric antigen receptor

The subjects will be administered once.